FDA Brief

Warning letters Drugs

FDA warning letter to

GenoGenix LLC

High riskIssued Jan 20Posted Mar 3Center for Drug Evaluation and Research (CDER)

FDA warns GenoGenix over insanitary sterile compounding, endotoxin-contaminated NAD+, and unapproved drugs.

What happened

FDA inspected GenoGenix’s Boca Raton, Florida facility from July 14, 2025, to July 18, 2025, and issued a Form FDA 483 plus an amended Form FDA 483. FDA found sterile drug products made under insanitary conditions and multiple CGMP failures, plus subpotent products, an NAD+ lot with excessive bacterial endotoxins after three patients developed adverse symptoms, unapproved new drugs, and 503B reporting and labeling failures. The firm ceased drug production and distribution and on July 30, 2025 recalled sterile products within expiry due to lack of sterility assurance or microbial contamination.

What FDA found

  1. Drug products intended or expected to be sterile were prepared under insanitary conditions that could contaminate them.

    section 501(a)(2)(A) of the FDCA [21 U.S.C. § 351(a)(2)(A)]
  2. The firm did not establish or follow written procedures to prevent microbiological contamination of sterile drugs or validate aseptic and sterilization processes.

    21 CFR 211.113(b)
  3. The firm released injectable methylcobalamin 5,000 mcg/mL at 65.3% of label and injectable B Complex with dexpanthenol at 43.1% of label.

    section 501(c) of the FDCA [21 U.S.C. § 351(c)]
  4. An unopened vial of NAD+ lot GG121624-023 contained 3,360 EU/mL bacterial endotoxins after three patients developed low blood pressure, shaking, shivers, and body aches and went to the emergency room.

    section 501(c) of the FDCA [21 U.S.C. § 351(c)]
  5. The firm had no FDA-approved applications for compounded drugs or for repackaged semaglutide, tirzepatide, retatrutide, and Thymosin Beta-4.

    sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 355(a), 331(d)]; PHS Act section 351 [42 U.S.C. § 262] for Thymosin Beta-4
  6. The firm compounded with 5-amino-1-methylquinolinium iodide (5-Amino-1MQ) and NAD+, which are not on the 503B bulks list and were not on the drug shortage list.

    section 503B(a)(2)(A)(i) of the FDCA [21 U.S.C. § 353b(a)(2)(A)]

What FDA wants

FDA asks GenoGenix to correct the cited violations and provide adequate corrective action documentation; no response deadline is stated in the provided letter.

Who should pay attention

  • clinics and patients receiving compounded sterile injectables
  • outsourcing facilities and compounding pharmacies
  • companies repackaging or selling GLP-1 drugs such as semaglutide and tirzepatide

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk